We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+12.63%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$659M
AUM Growth
-$194M
Cap. Flow
-$205M
Cap. Flow %
-31.16%
Top 10 Hldgs %
43.01%
Holding
164
New
28
Increased
30
Reduced
27
Closed
56

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$15.1M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.4M
3
FOLD
Amicus Therapeutics
FOLD
+$11.3M
4
NMTR
9 Meters Biopharma
NMTR
+$9.54M
5
MRK icon
Merck
MRK
+$8.77M

Top Sells

Rank Stock Value
1
CEL
Cellcom Israel, Ltd.
CEL
+$14M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$12.9M
3
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$9.22M
4
RXDX
Ignyta, Inc.
RXDX
+$9.19M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.07M

Sector Composition

Rank Sector Weight
1 Healthcare 75.21%
2 Technology 4.55%
3 Financials 1.71%
4 Communication Services 1.32%
5 Consumer Discretionary 0.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SCTL
51
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$4.01M 0.61%
+406,080
New +$3.41M
CRVS icon
52
Corvus Pharmaceuticals
CRVS
$1.12B
$3.71M 0.56%
321,430
+100,000
+45% +$946K
CYPH
53
Cypherpunk Technologies Inc
CYPH
$62.9M
$3.54M 0.54%
+42,709
New +$2.94M
MGNX icon
54
MacroGenics
MGNX
$235M
$3.4M 0.52%
135,000
-3,700
-3% -$89.9K
BHVN
55
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$3.38M 0.51%
+131,100
New +$3.92M
NTLA icon
56
Intellia Therapeutics
NTLA
$1.49B
$3.37M 0.51%
+160,000
New +$3.93M
ENDP
57
DELISTED
Endo International plc
ENDP
$3.27M 0.5%
+550,000
New +$3.84M
CTIC
58
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$3.25M 0.49%
833,633
– –
MTVA
59
MetaVia Inc
MTVA
$7.33M
$3.13M 0.48%
+7
New +$3.55M
CMTA
60
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$3.03M 0.46%
200,000
+37,000
+23% +$602K
QURE icon
61
uniQure
QURE
$3.03B
$3M 0.46%
+127,600
New +$2.78M
RGNX icon
62
Regenxbio
RGNX
$620M
$2.98M 0.45%
100,000
+77,893
+352% +$2.27M
CHRS icon
63
Coherus Oncology
CHRS
$217M
$2.98M 0.45%
+270,000
New +$2.95M
MA icon
64
Mastercard
MA
$502B
$2.9M 0.44%
16,525
+5,000
+43% +$855K
BOLD
65
DELISTED
Audentes Therapeutics, Inc
BOLD
$2.85M 0.43%
95,000
– –
LRCX icon
66
Lam Research
LRCX
$367B
$2.71M 0.41%
133,560
-32,240
-19% -$639K
ORLY icon
67
O'Reilly Automotive
ORLY
$72.9B
$2.68M 0.41%
162,660
-12,090
-7% -$204K
NEOS
68
DELISTED
Neos Therapeutics, Inc
NEOS
$2.66M 0.4%
320,692
+150,660
+89% +$1.44M
XFOR icon
69
X4 Pharmaceuticals
XFOR
$375M
$2.63M 0.4%
639
-857
-57% -$2.49M
PHXM
70
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$2.52M 0.38%
12,000
– –
QTTB icon
71
Q32 Bio
QTTB
$466M
$2.49M 0.38%
+7,389
New +$2.48M
CBIO
72
Crescent Biopharma
CBIO
$537M
$2.44M 0.37%
1,500
-1,750
-54% -$3.64M
VBIV
73
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$2.33M 0.35%
22,209
-4,458
-17% -$532K
EXPE icon
74
Expedia Group
EXPE
$35.4B
$2.09M 0.32%
18,900
-4,050
-18% -$471K
SRRA
75
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$2.07M 0.31%
25,000
+11,250
+82% +$1.28M
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2018 Portfolio in Review

As of Q1 2018, Sphera Funds Management held 164 positions worth $659M, down 23% from $852M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Sphera Funds Management withdrew a net $205M in Q1 2018, closing 56 positions and reducing 27 holdings. Its most notable exit was Cellcom Israel, Ltd., an estimated $14M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 59% a quarter earlier, followed by Technology and Financials.

Against the trend, Sphera Funds Management opened a new position in Regeneron Pharmaceuticals worth $14.3M.

  • Sphera Funds Management's largest Q1 2018 buy was Regeneron Pharmaceuticals: 41,500 shares worth $14.3M.
  • Sphera Funds Management added most to Shire pic in Q1 2018, an estimated $15.1M increase.
  • Sphera Funds Management's biggest Q1 2018 reduction was Sarepta Therapeutics, cutting an estimated $9.07M.
  • Sphera Funds Management fully exited Cellcom Israel, Ltd. in Q1 2018, selling an estimated $14M.
  • Sphera Funds Management's ten largest holdings make up 43% of its $659M portfolio in Q1 2018.
  • Sphera Funds Management opened 28 new positions and closed 56 in Q1 2018.
  • Sphera Funds Management's portfolio value fell 23% quarter-over-quarter to $659M.

Based on Sphera Funds Management's 13F filing for Q1 2018, filed 10 May 2018.